NCT03208023

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

RESIPI for Reducing Perioperative Major Adverse Cardiac Events: A Phase II Prospective Randomized Controlled Trial

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 155 (actual)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.

Detailed description

Modest elevations in cardiac biomarkers in the immediate postoperative period are associated with significantly increased risk of morbidity and mortality. The RESIPI model of hemodynamic monitoring and management in the perioperative period takes into account the dynamic interplay of vascular resistance, inotropy, and fluid management. This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.

Conditions

• Inotropy
• Fluid Management
• Cardiac Event
• Perioperative Cardiac Risk
• Vascular Resistance
• Hemodynamic Monitoring
• Hemodynamic Management
• Fluid Responsiveness

Interventions

Type	Name	Description
PROCEDURE	RESIPI Management Strategy	a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
OTHER	No intervention	No intervention

Timeline

• Start date: 2017-10-09
• Primary completion: 2018-11-01
• Completion: 2018-12-03
• First posted: 2017-07-05
• Last updated: 2022-11-17

Locations

1 site across 1 country: United States